ストックスクリーナーアプリを入手
33.15
2.50%
0.81
前日終値:
$32.34
開ける：
$32.72
24時間の取引高:
354.75K
Relative Volume:
0.67
時価総額：
$1.77B
収益：
$651.97M
当期純損益:
$59.71M
株価収益率:
30.99
EPS:
1.0696
ネットキャッシュフロー:
$172.03M
1週間 パフォーマンス:
+4.57%
1か月 パフォーマンス:
+2.22%
6か月 パフォーマンス:
-10.82%
1年 パフォーマンス:
+22.10%
1日の値動き範囲:
$32.33
$33.20
1週間の範囲:
$31.32
$33.20
52週間の値動き範囲:
$25.53
$40.28
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
名前
Supernus Pharmaceuticals Inc
セクター
電話
301-838-2500
住所
9715 KEY WEST AVENUE, ROCKVILLE, MD
SUPN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
33.15 | 1.77B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
170.16 | 75.08B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
11.07 | 51.07B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 46.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.77 | 19.24B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
325.82 | 14.38B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-19 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-09-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | 再開されました | Jefferies | Buy |
| 2021-12-01 | 再開されました | Jefferies | Buy |
| 2021-04-13 | アップグレード | Jefferies | Hold → Buy |
| 2020-06-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 再開されました | Jefferies | Hold |
| 2019-11-08 | ダウングレード | Berenberg | Buy → Hold |
| 2019-11-07 | ダウングレード | Stifel | Buy → Hold |
| 2019-11-06 | ダウングレード | Jefferies | Buy → Hold |
| 2018-11-12 | 繰り返されました | B. Riley FBR | Buy |
| 2018-01-18 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | アップグレード | Janney | Neutral → Buy |
| 2017-11-08 | アップグレード | Stifel | Hold → Buy |
| 2017-10-19 | 開始されました | FBR & Co. | Buy |
| 2017-09-19 | ダウングレード | Stifel | Buy → Hold |
| 2017-07-17 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 開始されました | Janney | Neutral |
| 2017-06-01 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | アップグレード | Jefferies | Hold → Buy |
| 2015-11-05 | 繰り返されました | Northland Capital | Outperform |
| 2015-10-28 | 開始されました | Northland Capital | Outperform |
すべてを表示
Supernus Pharmaceuticals Inc (SUPN) 最新ニュース
Millennium Management LLC Trims Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus at Jefferies Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com South Africa
(SUPN) Trading Report - news.stocktradersdaily.com
Supernus at Jefferies Global Healthcare Conference: Strategic Insights - Investing.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Nuveen Asset Management LLC - Defense World
Supernus (SUPN) Partners with Jay Glazer for ADHD Awareness Series | SUPN Stock News - GuruFocus
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and R - GuruFocus
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals | SUPN Stock News - GuruFocus
Supernus Pharmaceuticals Partners with Jay Glazer for ADHD Awareness Series Featuring Insights from His Journey with Qelbree - Nasdaq
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD - GlobeNewswire
Jay Glazer and Wife Share Raw ADHD Story: How Treatment Changed Their Marriage - Stock Titan
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference - GlobeNewswire
Supernus (SUPN) to Protect Qelbree Patents Amid Generic Challenges | SUPN Stock News - GuruFocus
Supernus Pharmaceuticals Faces Patent Challenges for Qelbree - TipRanks
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference | SUPN Stock News - GuruFocus
Supernus CEO Fireside Chat: Latest CNS Pipeline Insights Coming at Major Healthcare Conference - Stock Titan
Supernus Announces Paragraph IV ANDA Filings for Qelbree® | SUPN Stock News - GuruFocus
Supernus to Defend Qelbree Patents Until 2035 Against Multiple Generic Challengers - Stock Titan
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
(SUPN) Investment Report - news.stocktradersdaily.com
Bank of America Corp DE Has $13.49 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrep - GuruFocus
Busy Philipps Partners with Supernus (SUPN) to Empower Women wit - GuruFocus
Supernus Pharmaceuticals Partners with Busy Philipps for "Ms. Represented" Campaign to Empower Women with ADHD - Nasdaq
Busy Philipps Empowers Women with ADHD to Go from Feeling - GlobeNewswire
Busy Philipps Reveals ADHD Journey: New Campaign Spotlights Hidden Women's Symptoms - Stock Titan
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being 'Ms. Represented' in First-of-its-Kind Campaign with Supernus Pharmaceuticals - The Manila Times
Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Strong-Buy” at StockNews.com - Defense World
The Manufacturers Life Insurance Company Sells 797 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock? - Nasdaq
Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality - simplywall.st
Solid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A Business - Yahoo Finance
Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Wednesday - Defense World
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Supernus Pharmaceuticals, Inc. investment - ACCESS Newswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com - Defense World
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Stock Surge: Supernus Pharmaceuticals Inc (SUPN) Closes at 30.94, Marking a -4.59 Increase/Decrease - DWinneX
Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsSUPN - ACCESS Newswire
Supernus Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LP - Defense World
SUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Earnings call transcript: Supernus Q1 2025 earnings miss expectations By Investing.com - Investing.com Canada
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Supernus: Q1 Earnings Snapshot - CTPost
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus
Earnings call transcript: Supernus Q1 2025 earnings miss expectations - Investing.com
Supernus Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Est - GuruFocus
SUPN Reports Higher than Expected Q1 Revenue at $149.8M | SUPN S - GuruFocus
Supernus Pharmaceuticals Inc (SUPN) 財務データ
収益
当期純利益
現金流量
EPS
Supernus Pharmaceuticals Inc (SUPN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| DEC TIMOTHY C | Senior Vice-President & CFO |
Mar 10 '25 |
Option Exercise |
0.00 |
3,800 |
0 |
13,636 |
| Khattar Jack A. | President, CEO |
Mar 07 '25 |
Option Exercise |
0.00 |
38,640 |
0 |
992,219 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Mar 07 '25 |
Option Exercise |
0.00 |
2,625 |
0 |
16,507 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 26 '25 |
Option Exercise |
0.00 |
5,760 |
0 |
17,683 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 21 '25 |
Option Exercise |
0.00 |
1,650 |
0 |
11,799 |
| Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Option Exercise |
0.00 |
1,875 |
0 |
8,780 |
| Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Sale |
39.15 |
927 |
36,292 |
7,853 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 21 '25 |
Option Exercise |
0.00 |
1,125 |
0 |
9,576 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Option Exercise |
29.61 |
9,477 |
280,614 |
19,626 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Sale |
39.70 |
9,477 |
376,237 |
10,149 |
3.50%
大文字化:
|
ボリューム (24 時間):